Grant Langdon - Concepedia

Author

Grant Langdon

University of Cape Town

Also Known As

G Langdon, G. Langdon, Georgia Langdon, Grant Langdon

Publications

955

Citations

H-Index

Concepts

All Affiliations

University of Cape Town Pfizer (United Kingdom)Uppsala University Pfizer (United States)Medicines for Malaria Venture

About

Grant Langdon is an author at University of Cape Town specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	259
2	Pharmacology	5	5	152
3	Health Sciences	1	1	107
4	Allergy	1	1	107
5	Immunology	1	1	107

Grant Langdon

Publications

904

Citations

H-Index

Page 1

	Year	Citations
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study Rocío Lledó‐García, Shikiko Watanabe, Grant Langdon, Science Translational Medicine	2017	195
Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption Justin Wilkins, Radojka M. Savić, Mats O. Karlsson, Antimicrobial Agents and Chemotherapy	2008	147
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients Justin Wilkins, Grant Langdon, Helen McIlleron, British Journal of Clinical Pharmacology	2011	107
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Blood Advances ImmunohematologyIsolated ThrombocytopeniaImmunodeficienciesImmunologyPharmacotherapy	2020	107
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients Justin Wilkins, Grant Langdon, Helen McIlleron, European Journal of Clinical Pharmacology Pulmonary TuberculosisMedicineTuberculosis PreventionTuberculosisPharmacotherapy	2006	78
Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers Phumla Sinxadi, Cristina Donini, Hilary Johnstone, Antimicrobial Agents and Chemotherapy	2020	58
First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection Mohamed Farouk Chughlay, Emilie Rossignol, Cristina Donini, British Journal of Clinical Pharmacology	2020	41
Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM Grant Langdon, Ivelina Gueorguieva, Leon Aarons, European Journal of Clinical Pharmacology Pharmacokinetic ModelingPhysiologically-based Pharmacokinetic ModelingMedicinePhysiologyClinical Whole-body	2007	36
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study Mohamed Farouk Chughlay, Myriam El Gaaloul, Cristina Donini, American Journal of Tropical Medicine and Hygiene	2021	31
Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Grant Langdon, Justin Wilkins, Smith Pj, PubMed	2004	23

Page 1